Kayla Castaneda
Women's Health · El Paso, TXNPI 1174773857
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Eisai Inc. at 48.6% of the total. 2025 is the largest year on record at $40,240, more than ten times the $657 reported in 2021. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $154.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$26K
- GSK$14K
- Pfizer$5K
- AstraZeneca$2K
- Medtronic$939
- Merck$800
- plus $5K from 29 others
What the payments were for
- Consulting fees$1,5983%
- Speaking & faculty fees$26,54850%
- Travel & lodging$12,56624%
- Food & beverage$11,63122%
- Education$3091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 93 | $25,587 |
| GSK | 60 | $14,462 |
| Pfizer | 7 | $4,503 |
| AstraZeneca | 45 | $1,632 |
| Medtronic | 21 | $939 |
| Merck | 38 | $800 |
| Genmab U.S., Inc. | 14 | $666 |
| Globus Medical | 4 | $455 |
| AbbVie | 9 | $415 |
| Daiichi Sankyo Inc. | 6 | $406 |
| Exelixis Inc. | 3 | $353 |
| Regeneron Healthcare Solutions, Inc. | 3 | $260 |
| Ipsen Biopharmaceuticals, Inc | 3 | $233 |
| Pharmacosmos Therapeutics Inc. | 2 | $205 |
| Johnson & Johnson | 2 | $204 |
| Jazz Pharmaceuticals Inc. | 2 | $201 |
| Incyte Corporation | 1 | $125 |
| Intuitive Surgical | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
| Adaptive Biotechnologies Corporation | 1 | $111 |
| Mirati Therapeutics, Inc. | 1 | $101 |
| Seagen Inc. | 1 | $100 |
| Karyopharm Therapeutics Inc. | 1 | $99 |
| Myriad Women's Health, Inc. | 1 | $84 |
| Geron Corporation | 1 | $80 |
| AVEO Pharmaceuticals, Inc. | 1 | $76 |
| Clovis Oncology, Inc. | 4 | $68 |
| Bayer | 4 | $63 |
| Astellas Pharma US Inc | 2 | $51 |
| Aspira Women's Health Inc | 2 | $41 |
| Caris MPI, Inc. | 2 | $30 |
| Stryker | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,652 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 31 | $419,627 |
| Gabapentin | 87 | $1,452 |
| Ondansetron OdtOndansetron | 63 | $908 |
| Estradiol (Once Weekly)Estradiol | 11 | $730 |
| Pregabalin | 25 | $392 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $300 |
| Clobetasol Propionate | 26 | $250 |
| Olanzapine | 18 | $183 |
| Mirtazapine | 12 | $143 |
| Duloxetine Hcl | 11 | $113 |
| Alendronate Sodium | 37 | $101 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $98 |
| Triamcinolone Acetonide | 24 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $1,632 | $419,62731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 609 women's health providers in Texas.
Other women's health in El Paso
- Christina BlancoEl Paso$14K
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
- Shelagh LarsonFort Worth$43K
- Amanda ArmondAustin$17K
- Joann St PierreHouston$15K
- Ricshonda MilburnGalveston$13K
- Sandra EastlingLubbock$12K
- Lori WinkHouston$9K
- Christina HicksDallas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.